12-15 MOLECULAR DIAGNOSTICS INC.

12-15 Molecular Diagnostics Inc. specializes in the design, development, and manufacturing of advanced molecular diagnostic systems and reagents for government and public health applications. Leveraging expertise in nucleic acid amplification, real-time PCR, and multiplex assay platforms, the company delivers precision diagnostic solutions tailored for infectious disease detection, biothreat identification, and clinical surveillance. Their technical capabilities include assay validation, ISO 13485-compliant production processes, and integration of lab-on-a-chip technologies to enable rapid, field-deployable testing. The firm’s focus on molecular biology instrumentation and closed-system diagnostic platforms positions it as a niche provider of high-specificity, low-contamination diagnostic tools for mission-critical environments. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal partnership can be inferred. Similarly, without contract data, the scope of work performed for any government entity remains undocumented. The company’s primary NAICS code, 334516, corresponds to the manufacturing of laboratory diagnostic instruments, indicating a focus on producing in vitro diagnostic devices and associated consumables. This places them within the biomedical instrumentation sector, serving markets requiring FDA-cleared or CE-marked diagnostic systems with stringent quality controls and traceability. 12-15 Molecular Diagnostics Inc. is structured as a small business (2L) and is headquartered in East Haven, Connecticut. The firm holds no active government certifications, and its market presence is confined to its physical location with no indication of multi-site operations or federal subcontracting networks. Its positioning is that of a specialized manufacturer with technical depth in molecular diagnostics, operating independently within the federal biomedical supply chain.